INSM

Insmed Inc

INSM, USA

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

https://www.insmed.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
INSM
stock
INSM

Insmed (INSM): Assessing Valuation After a Strong Year of Share Price Gains Yahoo Finance

Read more →
INSM
stock
INSM

TD Cowen Raises Price Target for Insmed (INSM) to $269 | INSM Stock News GuruFocus

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$216.8235

Analyst Picks

Strong Buy

14

Buy

5

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

43.46

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-39.13 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-15.67 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-156.09 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.50

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 87.80% of the total shares of Insmed Inc

1.

Darwin Global Management, Ltd.

(9.1518%)

since

2025/06/30

2.

Vanguard Group Inc

(8.3475%)

since

2025/06/30

3.

JPMorgan Chase & Co

(7.3975%)

since

2025/06/30

4.

T. Rowe Price Associates, Inc.

(5.3132%)

since

2025/06/30

5.

BlackRock Inc

(5.2714%)

since

2025/06/30

6.

Baker Bros Advisors LP

(3.6489%)

since

2025/06/30

7.

Capital Research & Mgmt Co - Division 3

(3.5382%)

since

2025/06/30

8.

JPMorgan Large Cap Growth I

(3.3571%)

since

2025/07/31

9.

Vanguard Total Stock Mkt Idx Inv

(2.7182%)

since

2025/07/31

10.

FMR Inc

(2.4096%)

since

2025/06/30

11.

Capital Group Growth Fnd of Amer Comp

(2.2405%)

since

2025/06/30

12.

American Funds Growth Fund of Amer A

(2.2405%)

since

2025/06/30

13.

Vanguard Small Cap Index

(2.0923%)

since

2025/07/31

14.

State Street Corp

(2.0238%)

since

2025/06/30

15.

US Small-Cap Growth II Equity Comp

(1.7105%)

since

2025/06/30

16.

D. E. Shaw & Co LP

(1.6192%)

since

2025/06/30

17.

Geode Capital Management, LLC

(1.5805%)

since

2025/06/30

18.

Artisan Partners Limited Partnership

(1.568%)

since

2025/06/30

19.

BioPharma Credit Ord

(1.4985%)

since

2024/12/31

20.

RTW INVESTMENTS, LLC

(1.4593%)

since

2025/06/30

21.

Ameriprise Financial Inc

(1.3994%)

since

2025/06/30

22.

Adage Capital Partners Gp LLC

(1.3528%)

since

2025/06/30

23.

Vanguard Small Cap Growth Index Inv

(1.1783%)

since

2025/07/31

24.

T. Rowe Price New Horizons

(1.16%)

since

2025/07/31

25.

T. Rowe Price Health Sciences

(1.1473%)

since

2025/07/31

26.

Franklin Resources Inc

(1.1118%)

since

2025/06/30

27.

HHG PLC

(1.0849%)

since

2025/06/30

28.

Duquesne Family Office LLC

(1.0661%)

since

2025/06/30

29.

Millennium Management LLC

(1.0038%)

since

2025/06/30

30.

Holocene Advisors, LP

(0.9541%)

since

2025/06/30

31.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9264%)

since

2025/07/31

32.

American Funds SMALLCAP World A

(0.8709%)

since

2025/06/30

33.

JPMorgan Growth Advantage A

(0.7801%)

since

2025/07/31

34.

JPM US Mid Cap Growth-Composite

(0.768%)

since

2025/06/30

35.

JPMorgan Mid Cap Growth I

(0.7656%)

since

2025/07/31

36.

T. Rowe Price All-Cap Opportunities Fund

(0.6717%)

since

2025/07/31

37.

T. Rowe Price US All-Cap Opp Eq Comp

(0.6717%)

since

2025/06/30

38.

iShares Biotechnology ETF

(0.5833%)

since

2025/08/31

39.

SPDR® S&P Biotech ETF

(0.5664%)

since

2025/08/31

40.

T. Rowe Price New Horizons Tr-A

(0.5546%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-1.24

Latest Release

Date

2025-09-30

EPS Actual

-1.75

EPS Estimate

-1.32

EPS Difference

-0.43

Surprise Percent

-32.5758%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.